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Abstract
Evasion of apoptosis is a hallmark of cancer, and reversing this process by inhibition of survival signaling pathways
is a potential therapeutic strategy. Phosphoinositide 3-kinase (PI3K) signaling can promote cell survival and is
upregulated in solid tumor types, including colorectal cancer (CRC), although these effects are context dependent.
The role of PI3K in tumorigenesis combined with their amenability to specific inhibition makes them attractive drug
targets. However, we observed that inhibition of PI3K in HCT116, DLD-1, and SW620 CRC cells did not induce
apoptotic cell death. Moreover, these cells were relatively resistant to the Bcl-2 homology domain 3 (BH3) mimetic
ABT-737, which directly targets the Bcl-2 family of apoptosis regulators. To test the hypothesis that PI3K inhibition
lowers the apoptotic threshold without causing apoptosis per se, PI3K inhibitors were combined with ABT-737. PI3K
inhibition enhanced ABT-737–induced apoptosis by 2.3- to 4.5-fold and reduced expression levels of MCL-1, the
resistance biomarker for ABT-737. PI3K inhibition enhanced ABT-737–induced apoptosis a further 1.4- to 2.4-fold
in CRC cells with small interfering RNA–depleted MCL-1, indicative of additional sensitizing mechanisms. The obser-
vation that ABT-737–induced apoptosis was unaffected by inhibition of PI3K downstream effectors AKT and mTOR,
implicated a novel PI3K-dependant pathway. To elucidate this, an RNA interference (RNAi) screen of potential down-
stream effectors of PI3K signaling was conducted, which demonstrated that knockdown of the TEC kinase BMX
sensitized to ABT-737. This suggests that BMX is an antiapoptotic downstream effector of PI3K, independent of AKT.
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Introduction
Single-agent treatments rarely prove sufficient for cancer cure. This is
in part due to a variety of innate or acquired, drug-specific, or pleio-
tropic drug resistance mechanism(s), one of which is suppression of
drug-induced cell death. Consequently, there is considerable motiva-
tion to overcome drug resistance mechanisms by identifying rational
combinations of molecular targeted drugs. To aid this, the US Food
and Drug Administration (FDA) is considering early-phase drug
combination trials without the necessity for prior single-agent
approval [1]. Historically, choice of drug combinations is predicated
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on nonoverlapping drug toxicities; however, the concept of targeting
multiple different hallmarks of cancer is an emerging approach [2].
Two such hallmarks are sustained inappropriate proliferative signal-
ing and suppression of apoptotic cell death [2]. Molecular features
that contribute to these hallmarks in several human tumors, includ-
ing colorectal cancer (CRC), are aberrations in the phosphoinositide
3-kinase (PI3K) signaling pathway and up-regulation of antiapopto-
tic Bcl-2 family proteins. This study examines the combined effect
of inhibiting PI3K signaling and interrupting the protein-protein
interactions between proapoptotic and antiapoptotic members of the
Bcl-2 family in CRC cells.
PI3K phosphorylates the 3-hydroxy group of phosphatidylinositol
lipid rings to generate a secondary messenger that is implicated in
many intracellular signaling pathways. The most studied are the class
I PI3Ks, which phosphorylate phosphatidylinositol-4,5-bisphosphate
generating phosphatidylinositol-3,4,5-triphosphate [PtdIns(3,4,5)P3]
[3]. PtdIns(3,4,5)P3 is a docking site for a number of proteins that
contain PtdIns(3,4,5)P3-binding motifs such as pleckstrin homology
(PH) domains, frequently leading to activation of the docked protein.
The best characterized effectors of the pathway are phosphoinositide-
dependent kinase 1 (PDK1) and AKT (AKA protein kinase B). PDK1
and AKT bind to PtdIns(3,4,5)P3, allowing PDK1 to phosphorylate
and activate AKT [4]. Activation of AKT has multiple cell fate out-
comes including increased cell survival, sustained cell proliferation,
and enhanced cell migration, all of which have potential to promote
oncogenesis [5]. Aberrant PI3K signaling is implicated in many cancer
types. For example, loss of the PI3K antagonistic phosphatase PTEN
and activating mutations in PIK3CA, the gene encoding the catalytic
PI3K subunit p110α, are among the most common genetic aberrations
in cancer [6]. Consequently, the PI3K signaling pathway is a major
focus of drug discovery programs, with multiple small-molecule in-
hibitors targeting PI3K, AKT, and other PI3K pathway components
undergoing clinical trials [6]. Multiple lines of preclinical evidence
suggest that PI3K signaling acts to suppress apoptosis through mecha-
nisms including the modulation of Bcl-2 family proteins that control
the release of potent apoptogens from mitochondria [5]. However,
despite this body of evidence, apoptosis is not induced in many cancer
cell lines after specific inhibition of PI3K pathway signaling [7,8].
Furthermore, emerging evidence shows that, whereas in some cell
types, combining PI3K inhibition with conventional chemotherapeutic
agents induces apoptosis [9,10], this is not the case with CRC cells [7],
a disease where aberrant PI3K activation is common.
Drug development efforts to disrupt interactions between proapop-
totic and antiapoptotic proteins of the Bcl-2 family yielded the Bcl-2
homology domain 3 (BH3) mimetic class of drugs [11]. The “poster-
child” BH3 mimetic ABT-737 and its related clinical candidate navi-
toclax readily induce apoptosis in small cell lung cancer in vitro and
in vivo as a single agent [12] and kill lymphoma cell lines and primary
lymphoma cells ex vivo [12,13], and navitoclax has demonstrated prom-
ising results in a phase I clinical trial in patients with chronic lympho-
cytic leukemia [14]. However, in several cancer cell types, including
CRC, ABT-737 treatment alone does not induce apoptosis at clini-
cally relevant concentrations [15]. In a broad range of cancer cell
types, ABT-737 acts synergistically with a variety of conventional
and novel chemotherapeutic agents [16], including agents that tar-
get the PI3K pathway [17,18]. This suggests that a lowering of the
apoptotic threshold by ABT-737 facilitates the coupling of drug-
induced damage and/or the interruption of survival signaling events
to the commitment to apoptotic cell death. Therefore, the hypothesis
tested in this study was that PI3K pathway ablation using small-
molecule inhibitors could “prime” CRC cells for apoptosis but that
cell death would only be realized if the actions of antiapoptotic Bcl-2
family proteins were negated by a BH3 mimetic.
Materials and Methods
Cell Culture and Drugs
HCT116, DLD-1 [American Type Culture Collection (ATCC),
Manassas, VA], and isogenic pairs of HCT116 and DLD-1 expressing
only wild-type or mutant PIK3CA (a kind gift from B. Vogelstein)
were cultured in McCoy’s 5A media (Life Technologies, Inc, Paisley,
United Kingdom) supplemented with 10% FBS (BioWest, Nuaillé,
France). SW620 (ATCC) were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% FBS and glutamine (Life Technolo-
gies, Inc). All cells were maintained in a humidified atmosphere at 37°C
and 5% CO2. Cell lines were authenticated using the AmpFlSTR
system (Applied Biosystems, Paisley, United Kingdom) during the
study. ABT-737 (a kind gift from AbbVie, Chicago, IL), PI-103,
rapamycin, Akti1/2, KU-0063794 (Merck, Nottingham, United
Kingdom), GDC-0941, MK-2206, and PCI-32765 (Selleck Chemi-
cals, Houston, TX) were all dissolved to 10 mM in DMSO (Sigma,
Dorset, United Kingdom) and stored as single use aliquots at −20°C/
−80°C (Figure W1).
Concentration Response
Cells were seeded into 96-well plates. After 24 hours, cells were
treated with the indicated concentration of drug(s) and cultured for a
further 72 hours in the presence of drug(s). Plates were stained with
sulforhodamine B (SRB) and processed as previously described [7] to
give an indication of cellular biomass. To determine logGI50, log drug
concentration was plotted against raw absorbance, and nonlinear
curve fit analysis was performed (GraphPad Prism; GraphPad Soft-
ware, La Jolla, CA). Statistical analysis was carried out on three
independent logGI50 readings and transformed to growth inhibition
50 (GI50) for presentation. For display purposes only, drug concentra-
tion (log scale) has been plotted against normalized absorbance.
Western Blot Analysis
Cell lysis and Western blot analysis were carried out as previously
described [7]. The following primary antibodies were used: rabbit
anti-pS473AKT (No. 4058), rabbit anti-AKT (No. 9297), rabbit
anti-pT246 40-kDa proline-rich AKT substrate (PRAS40) (No. 2997),
rabbit anti-PRAS40 (No. 2691), pS240/244S6 (No. 4838), rabbit
anti-S6 (No. 2217), rabbit anti–cleaved caspase 3 (No. 9661), rabbit
anti-PARP (No. 9542), rabbit anti-Bax (No. 2774; all from Cell
Signaling Technology, Danvers, MA), mouse anti–Bcl-2 (M0887;
Dako, Glostrup, Denmark), rabbit anti–BCL-XL (No. 610211;
Becton Dickinson, Oxford, United Kingdom), mouse anti-human
MCL-1 (No. 559027; Becton Dickenson), rabbit anti–MCL-1
(sc819; Santa Cruz Biotechnology, Inc, Dallas, TX), rabbit anti-Bad
(AF819; R&D Systems, Minneapolis, MN), rabbit anti-Bim (No.
202000; Merck), mouse anti-Bak (AM03; Merck), mouse anti–α-
tubulin (CP06; Merck), and mouse anti-GAPDH (G9545; Sigma).
Measurement of Apoptosis
Annexin V/7-aminoactinomycin D (7AAD) flow cytometry was
performed as previously described [7]. For assessment of Bak con-
formational change, cells were cultured in a 96-well plate and
148 BMX Acts Downstream of PI3K to Promote Survival Potter et al. Neoplasia Vol. 16, No. 2, 2014
treated with the indicated drug(s) for 24 hours. Cells were fixed with
1% formaldehyde and sent to Imagen Biotech (Cheshire, United
Kingdom) where immunofluorescent staining for conformationally
changed Bak and high-content analysis were carried out using pro-
prietary protocols using Bak conformation–specific antibodies. Real-
time assessment of cells with activated Caspase 3/7 was carried out
using the CellPlayer apoptosis Caspase 3/7 reagent (Essen BioScience,
Ann Arbor, MI) following manufacturer’s recommendations. Cells
were placed in an IncuCyte (Essen BioScience) and imaged every
2 hours. The number of fluorescent cells per field of view was de-
termined using IncuCyte software (Essen BioScience) following
manufacturer’s recommendations.
RNA Interference (RNAi)
siRNA SMARTpools or individual oligos (Thermo Scientific,
Leicestershire, United Kingdom) were transfected into SW620 or
HCT116 cells using DharmaFECT 2 (Thermo Scientific) according
to manufacturer’s instructions. For the small interfering RNA (siRNA)
library screen, cells were reverse transfected with 5 pmol of siRNA
in 6 wells of a 96-well plate per SMARTpool and left for 48 hours,
3 wells were treated with 4 μM ABT-737, and 3 wells were treated
with DMSO equivalent. For other siRNA experiments, siRNA were
transfected in six-well plates, reseeded into appropriate culture vessels
24 hours later, and drug treated after another 24 hours. Calcula-
tion of robust z score is described in Supplemental Materials and
Methods section.
Real-Time Quantitative Polymerase Chain Reaction
Quantitative polymerase chain reaction (qPCR) was carried out as
previously described [19]. Assays for bone marrow tyrosine kinase gene in
chromosome X protein (BMX), SOS1, and SGK1 were designed with
the Roche (West Sussex, United Kingdom) Universal ProbeLibrary
Assay Design Center.
Statistical Analysis
Unpaired, two-tailed t tests were performed in Excel (Microsoft,
Redmond, WA) to determine significance. P < .05 was consid-
ered significant.
Results
PI-103 Sensitized CRC Cell Lines to ABT-737
The purpose of this study was to investigate the effect of combin-
ing ABT-737 with PI3K pathway inhibitors in CRC cell lines. The
lines used were HCT116 and DLD-1, which carry oncogenic acti-
vating mutations in PIK3CA, and SW620 cells that are wild type for
PIK3CA [20]. All three cell lines also harbor mutant KRAS (www.
sanger.ac.uk/genetics/CGP/cosmic/), which can activate the PI3K
signaling pathway [4]. All cell lines were responsive to the PI3K/
mammalian target of rapamycin (mTOR) inhibitor PI-103 in the
SRB assay, which measures cellular biomass, with GI50 values of
288 nM in HCT116 [95% confidence interval (CI) = 255-325 nM],
184 nM in DLD-1 (95% CI = 132-256 nM), and 636 nM in SW620
cells (95% CI = 508-797 nM) (Figure W2A). The phosphorylation of
PI3K and/or mTOR effectors AKT, PRAS40, and S6 was inhibited by
PI-103 in all cell lines (Figure W2B), confirming that PI-103 inhibited
PI3K and mTOR. To determine whether PI-103 treatment affected
CRC cell sensitivity to ABT-737, HCT116, SW620, and DLD-1 cells
were treated concomitantly with PI-103 and/or ABT-737 (Figure 1A
and Table 1). All cell lines exhibited a concentration-dependent re-
sponse to ABT-737 alone, and the ABT-737 GI50 was reduced sig-
nificantly in a concentration-dependent manner by PI-103. This is
consistent with PI3K inhibition sensitizing CRC cells to ABT-737.
The observation that PI-103 increased the sensitivity toward ABT-
737 irrespective of PIK3CA mutation status suggests that PIK3CA
mutation is not essential for this effect.
PI-103 Enhanced ABT-737–Induced Apoptosis
The effect of PI-103 on the levels of ABT-737–induced apoptosis
was determined by several methods. First, the effect of ABT-737
and/or PI-103 on caspase 3 and PARP cleavage was determined by
Western blot analysis (Figure 1B). ABT-737 alone induced some
caspase 3 and PARP cleavage, whereas PI-103–only treatment had
no effect. Combining the two agents increased caspase 3 and PARP
cleavage, suggesting that the combination caused more apoptosis
than either agent alone. The effect of ABT-737 and PI-103 on the
externalization of phosphatidylserine, another classic biomarker of
apoptosis, was determined by flow cytometry in HCT116 and SW620
cells (Figure 1C ). In both cases, neither PI-103 nor ABT-737 alone
caused a significant level of apoptosis compared to untreated cells,
whereas combining ABT-737 and PI-103 gave significantly more
apoptosis than any other condition.
PI3K signaling can promote numerous antiapoptotic mechanisms
that act upstream or downstream of cytochrome c release from mito-
chondria, for example, Bad sequestration and caspase 9 inhibition,
respectively [21,22]. To determine whether the PI-103–induced
ABT-737 sensitization was upstream of cytochrome c release, the per-
centage of HCT116 cells exhibiting the early activating N-terminal
conformational change in the multidomain proapoptotic protein
Bak [23] was assessed by immunofluorescence. The combination of
PI-103 and ABT-737 resulted in a significantly higher proportion of
cells with activated Bak than either agent alone (Figure 1D). This
confirmed that PI-103 sensitized CRC cells to ABT-737–induced
apoptosis and that this effect was mediated upstream of cytochrome
c release.
ABT-737 Sensitization Was Not Solely due to
MCL-1 Down-Regulation
There is precedence for PI3K inhibition affecting several Bcl-2 fam-
ily members including Bad, Bim, Bcl-2, MCL-1, and Bax [5]. When
the effect of PI-103 on expression levels of 10 Bcl-2 family members
was assessed byWestern blot analysis in HCT116 and SW620 cells, the
only observed change was a reduction in MCL-1 level (Figure 2A).
MCL-1 is an established resistance biomarker for ABT-737, due to
the poor affinity of ABT-737 for this antiapoptotic Bcl-2 family
member [24,25]. Moreover, MCL-1 stability is known to be decreased
by PI3K inhibition due to activation of GSK3β [26]. To test the
hypothesis that PI-103–induced sensitivity to ABT-737 was solely
due to a reduction of MCL-1 levels, MCL-1 was depleted by siRNA
(Figure 2B), and the effect of PI-103 on ABT-737 sensitivity was
reassessed. If the effect of PI3K inhibition on ABT-737 sensitivity is
mediated only through MCL-1 down-regulation, treatment with
PI-103 should not further sensitize MCL-1–depleted cells to ABT-
737. MCL-1 knockdown significantly sensitized both HCT116 and
SW620 to ABT-737, reducing the GI50 to a similar extent to that in
cells transfected with nontargeting siRNA and treated with PI-103
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(Figure 2C and Table W1). However, PI-103 significantly increased
sensitivity to ABT-737 in MCL-1 knockdown cells. To determine
whether this additional increase in ABT-737 sensitivity was due to
apoptosis, cells were transfected with nontargeting siRNA or MCL-1–
specific siRNA, treated with combinations of ABT-737 and/or
PI-103, and analyzed by annexin V/7AAD flow cytometry (Figure 2D).
This confirmed that, in MCL-1–depleted HCT116 and SW620 cells,
PI-103 treatment increased ABT-737–induced apoptosis. One experi-
mental caveat is that, whereas MCL-1 was clearly depleted by siRNA, a
detectable level remained, and PI-103 could be reducing the MCL-1
levels further (beyond the resolution of the assay). Thus, the increased
apoptosis observed could still be MCL-1 dependent. To address this,
similar studies were performed in MCL-1−/− mouse embryonic fibro-
blasts (MEFs). MCL-1 knockout was confirmed (Figure W3A), and
combining ABT-737 and PI-103 gave a significantly greater decrease
in colony formation than either agent alone (FigureW3B). Furthermore,
the combination gave enhanced cell death in parental and MCL-1−/−
MEFs (Figure W3C ). Although the mechanism of PI-103–induced
sensitization to ABT-737 may be different between CRC cell lines
and MEFs, this further demonstrates that MCL-1 is not essential for
PI-103–induced sensitization. Taken together, these data suggest that,
although reduced levels of MCL-1 in PI-103–treated cells caused
Figure 1. PI-103 sensitized CRC Cell Lines to ABT-737–induced apoptosis. (A) Cells were exposed to DMSO or the indicated concen-
tration of PI-103 and the indicated concentration of ABT-737 for 3 days. Cells were fixed and stained with SRB, and the absorbance
relative to untreated (UnT) cells was determined relative to DMSO or PI-103 only–treated cells as appropriate for individual concentration
response curves. (B–D) Cells were treated with the indicated combinations of 4 μMABT-737 (A and B) or 8 μMABT-737 (C) and 2 μMPI-103
for 24 hours. (A) The level of cleaved caspase 3, full-length PARP, cleaved PARP, and α-tubulin was assessed by Western blot analysis.
Results are representative of three independent experiments. (B) Cells were stained with allophycocyanin (APC)-conjugated annexin V
and 7AAD, and the percentage of annexin V–positive/7AAD-negative cells was determined by flow cytometry. (C) Cells were fixed and
stained for conformationally changed BAK, and the percentage of positive cells was determined by immunofluorescence. All graphs
represent the means of three independent experiments carried out in triplicate (A) or duplicate (C and D) ± SEM. *P < .05 according to
two-tailed unpaired t test.
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sensitization to ABT-737, there are additional MCL-1–independent
events that influence the response to ABT-737.
ABT-737 Sensitization Was due to Inhibition of PI3K but
Not AKT or mTOR
PI-103 is a dual PI3K/mTOR inhibitor; therefore, it was investi-
gated whether the effect of PI-103 on ABT-737 sensitivity was due
to PI3K inhibition, mTOR inhibition, and/or off-target effects. To
assess this, PI3K signaling was genetically altered. This was achieved
using HCT116 and DLD-1 cells, both of which normally express
one mutant and one wild-type PIK3CA allele (labeled Parental). In
the isogenic cell lines, one allele had been silenced by insertion of an
adeno-associated virus (AAV)–targeting system into exon 1 of either
the wild-type or mutant PIK3CA [27]. If the AAV inserted into the
wild-type PIK3CA allele, only the mutant protein was expressed,
resulting in higher PI3K activity compared to parental cells (labeled
Mutant). Conversely, if the AAV inserted into the mutant PIK3CA
allele, only the wild-type protein was expressed, resulting in lower
PI3K activity (labeled Wild-Type). This was confirmed by assessing
the level of AKT and PRAS40 phosphorylation in the isogenic cells
(Figure 3A). HCT116 and DLD-1 cells that only expressed wild-
type PIK3CA (low PI3K activity) were significantly more sensitive
to ABT-737 than corresponding parental cells (Figure 3B and
Table W2). HCT116 cells that only expressed mutant PIK3CA (high
PI3K activity) were significantly more resistant to ABT-737 than
HCT116 parental cells, and DLD-1 cells with mutant PIK3CA were
as resistant as parental cells. These data demonstrate that reduced
PI3K activity correlates with increased ABT-737 sensitivity, suggest-
ing that the observed effect of PI-103 was not due to off-target
effects. However, as both targets of PI-103 are components of the
PI3K signaling pathway, it remained unclear which target of PI-103
was responsible for the enhanced ABT-737 sensitivity. To investigate
this further, the effect of a panel of PI3K pathway inhibitors on ABT-
737 sensitivity was assessed in HCT116 and SW620 cells, specifically
GDC-0941, a class I PI3K-specific inhibitor [28], rapamycin, an
mTOR complex 1 (mTORC1)-specific inhibitor [29], KU-0063794,
an ATP-competitive mTOR inhibitor that inhibits mTORC1 and
mTORC2 but not PI3K [30], and AKTi1/2 and MK-2206, two
allosteric AKT inhibitors [31,32]. All agents were used at concentra-
tions that demonstrably inhibited their primary targets: GDC-0941
and KU-0063794 inhibited phosphorylation of AKT, PRAS40, and
S6; rapamycin inhibited S6 phosphorylation but increased AKT and
PRAS40 phosphorylation; and AKTi1/2 and MK-2206 inhibited
AKT and PRAS40 but not S6 phosphorylation (Figure 3C ). In
HCT116 and SW620 cells, GDC-0941 significantly sensitized to
ABT-737, whereas rapamycin and KU-0063794 were without effect
(Figure 3D and Table 2), suggesting that PI3K inhibition, rather than
mTORC1/2 inhibition, was responsible for ABT-737 sensitization.
Contrary to expectations, KU-0063794 did not sensitize to ABT-
737 despite the fact that AKT is a target of mTORC2 (Figure 3C )
and AKT is considered the main downstream effector of PI3K [6].
To explore this further, the effect of AKT inhibition on ABT-737 sen-
sitivity was investigated. In both cell lines, neither AKTi1/2 nor
MK-2206 had a significant effect on the sensitivity to ABT-737 (Fig-
ure 3D and Table 2), strongly suggesting that the downstream target of
PI3K responsible for ABT-737 sensitization is AKT independent and
implicating a novel, antiapoptotic PI3K-dependent, AKT-independent
signaling pathway. The ABT-737 concentration-response data were
verified by combining ABT-737 with each of the PI3K pathway inhi-
bitors and monitoring caspase activation in SW620 cells (Figure 3E).
Only PI-103 and GDC-0941 when combined with ABT-737 caused a
significant increase in the number of cells with activated caspase com-
pared to ABT-737 alone, consistent with the ABT-737 concentration-
response data. Furthermore, the PI-103–induced down-regulation
of MCL-1 was not observed with Akti1/2 or rapamycin treatment
(Figure W4), and neither Akti1/2 nor rapamycin was able to further
sensitize MCL-1–depleted SW620 cells to ABT-737 (Figure W5 and
Table W3). These data are consistent with at least two antiapoptotic
AKT/mTOR-independent pathways acting downstream of PI3K, only
one of which affects MCL-1 levels.
BMX Down-Regulation Sensitized to ABT-737
The secondary messenger generated by class I PI3K, PtdIns(3,4,5)
P3, has the potential to regulate many proteins in addition to AKT.
Indeed, there are reported to be >50 proteins that can bind to PtdIns
(3,4,5)P3 [3]. To determine whether any of these proteins may be
involved in the PI3K inhibition–induced sensitization to ABT-737,
a SMARTpool siRNA library targeting mRNA for each of 52 proteins
containing a PH domain that interacts with PtdIns(3,4,5)P3 and
other core PI3K pathway proteins was designed (Table W4). SW620
cells, which exhibited the greatest degree of sensitization to ABT-737
when PI3K signaling was inhibited, were transfected with each siRNA,
and the effect of ABT-737 treatment determined relative to non-
targeting siRNA–transfected cells (Figure 4A, left panel ). Four siRNAs
were shown to induce a significant (P < .05; robust z score < −0.9)
increase in ABT-737 sensitivity (Figure 4A, right panel, and Table W4).
Of these four siRNAs, BMX, SOS1, and SGK1 were chosen for
further analysis. A complete ABT-737 concentration response was
carried out on cells transfected with each of the individual siRNA
oligos that made up the SMARTpool with some oligos demonstrat-
ing a degree of sensitization for all three targets (Figures 4B and
W6). However, only oligos 1 and 3 targeting BMX produced a sig-
nificant sensitization to ABT-737 (P = .041 and .022, respectively;
Table W5). Furthermore, when the association between the level of
mRNA knockdown for each oligo set and the sensitization toward
ABT-737 was assessed, only knockdown of BMX significantly cor-
related with ABT-737 efficacy (P = .0015; Figures 4C and W6B). The
BMX siRNA oligos that gave the greatest degree of ABT-737 sensiti-
zation, SMARTpool, oligos 1 and 3, also caused the greatest reduc-
tion of BMX protein expression (Figure W7). BMX knockdown in
HCT116 cells also sensitized to ABT-737 (Figure 4D and Table W6).
Moreover, pharmacological inhibition of BMX with the TEC family
Table 1. Effect of PI-103 Treatment on ABT-737 GI50.
Cell Line Treatment ABT-737 GI50 (μM ± 95% CI) Significance*
HCT116 DMSO 5.80 (5.16-6.52)
0.5 μM PI-103 4.70 (4.30-5.15) 0.0495
1 μM PI-103 4.39 (3.78-5.09) 0.0439
2 μM PI-103 3.11 (2.26-4.29) 0.0231
SW620 DMSO 15.5 (14.2-16.8)
0.5 μM PI-103 5.07 (3.75-6.84) 0.0022
1 μM PI-103 2.88 (2.14-3.88) 0.0004
2 μM PI-103 2.22 (1.86-2.66) <0.0001
DLD-1 DMSO 5.35 (5.15-5.55)
0.5 μM PI-103 2.44 (2.19-2.71) 0.0002
1 μM PI-103 1.82 (1.60-2.07) 0.0001
2 μM PI-103 1.36 (0.99-1.87) 0.0011
*Two-tailed unpaired t test versus DMSO-treated GI50 for same cell line.
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Figure 2. Reduced MCL-1 level is not solely responsible for increased ABT-737 sensitivity. (A) HCT116 and SW620 cells were treated
with DMSO equivalent or 2 μM PI-103 for 24 hours, and the level of Bcl-2, BCL-XL, MCL-1, Bax, Bak, Bim, Bid, Puma, Bad, and Noxa was
determined by Western blot analysis. (B–D) HCT116 and SW620 cells were transfected with nontargeting siRNA (NT RNAi) or siRNA
targeting MCL-1 (MCL-1 RNAi) and plated for experiments 24 hours later. Cells were treated with 2 μM PI-103 for 24 hours, and the
effect on levels of MCL-1, pS473 AKT, and GAPDH was determined by Western blot analysis (B). RNAi cells were treated with 2 μM
PI-103 or DMSO equivalent and the indicated concentration of ABT-737 for 3 days and processed as in Figure 1A (C). RNAi cells were
treated with 2 μMPI-103 and/or 4 μMABT-737 (NT RNAi), 2 μMABT-737 (HCT116 MCL-1 RNAi), or 1 μMABT-737 (SW620 MCL-1 RNAi)
for 24 hours. Cells were stained with APC-conjugated annexin V and 7AAD and analyzed by flow cytometry (D). All blots are represen-
tative of three independent experiments, and all graphs represent the means of three independent experiments carried out in triplicate (C)
or duplicate (D) ± SEM. *P < .05, **P < .01, and ***P < .001 according to two-tailed unpaired t test.
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Figure 3. ABT-737 sensitization was PI3K dependent but AKT and mTOR independent. (A and B) Parental HCT116 and DLD-1 cells or
cells expressing only the mutant or wild-type PIK3CA allele were assessed for the level of pS473 AKT, total AKT, pT246 PRAS40, or
total PRAS40 by Western blot analysis (A) or exposed to the indicated concentrations of ABT-737 and processed as in Figure 1A (B).
(C) HCT116 and SW620 cells were exposed to 2 μMPI-103, 2 μMGDC-0941, 10 nM rapamycin, 2 μMKU-0063794, 1 μMAKTi1/2, or 1 μM
MK-2206 for 4 hours, and the effect on level of pS473 AKT, total AKT, pT246 PRAS40, total PRAS40, pS240/244 S6, and total S6 was
determined byWestern blot analysis. (D) HCT116 and SW620 cells were treated with the same concentrations of PI3K pathway inhibitors
as in C and the indicated concentrations of ABT-737 for 3 days and processed as in Figure 1A. (E) SW620 cells were treated with the same
concentrations of PI3K pathway inhibitors as in C with or without 4 μM ABT-737 plus CellPlayer Caspase 3/7 reagent, which fluoresces
after cleavage by caspases. Number of fluorescent cells was determined 8 hours after start of treatment. All blots are representative of
three independent experiments, and all graphs represent the means of three independent experiments carried out in triplicate (B and D)
or duplicate (E) ± SEM. **P < .01 and ***P < .001 according to two-tailed unpaired t test.
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kinase inhibitor PCI-32765 (ibrutinib [33]) in SW620, HCT116, and
DLD-1 cells sensitized to ABT-737 (Figures 4E and W8, and
Table W7). To determine whether BMX acted downstream of PI3K
with regard to ABT-737 sensitization, the effect of BMX knockdown
and PI-103 treatment on ABT-737 sensitivity was assessed. Knockdown
of BMX did not further sensitize PI-103–treated SW620 cells to
ABT-737 (Figure 4F and Table W8), suggesting that BMX-induced
sensitization to ABT-737 is downstream of PI3K. BMX inhibition,
either by RNAi or treatment with PCI-32765, did not affect expression
of MCL-1 (Figure W9), suggesting that sensitization to ABT-737
is through an MCL-1–independent mechanism. Together, these data
suggest that inhibition of BMX activity, either through knockdown or
pharmacological inhibition, can sensitize CRC cell lines to ABT-737.
This indicates that this PH domain–containing protein may represent a
key AKT-independent effector downstream of PI3K that is responsible
for PI3K inhibition–induced ABT-737 sensitization.
Discussion
In this study, we presented evidence that the inhibition of PI3K sig-
naling increased the sensitivity of CRC cells to ABT-737–induced
apoptosis. This effect was shown to be independent of AKT inhibi-
tion and in part due to factors additional to the observed MCL-1
down-regulation. Furthermore, we present data demonstrating that
inhibition of the TEC kinase BMX also sensitizes to ABT-737. This
raises the possibility that BMX is a key downstream target of PI3K
signaling mediating ABT-737 sensitivity and suggests that the PI3K/
BMX axis may have antiapoptotic activity in CRC cells.
Other studies in non–small cell lung cancer [18] and lymphoma
cell lines [17] have demonstrated that canonical PI3K pathway inhibi-
tion downstream of PI3K increased apoptosis in response to ABT-737
(or navitoclax). BCL-XL prevented PI3K inhibition–induced apoptosis
in non–small cell lung cancer cells, and this was overcome by ABT-737;
however, PI3K inhibition was phenocopied in AKT-depleted cells,
suggesting that the antiapoptotic effect of PI3K signaling was AKT
dependent [18]. Rapamycin increased navitoclax-induced apoptosis
in lymphoma cells in vitro and in vivo, although the mechanism of
action was not investigated [17]. Taken together, these three studies
suggest that there are different mechanisms downstream of PI3K sig-
naling to suppress ABT-737–induced apoptosis and that these mech-
anisms are context dependent. In support of this, a study investigating
the importance of AKT in cellular proliferation/survival across a panel
of human tumor cell lines revealed that a subset of cell lines (including
HCT116 and DLD-1) was dependent on PI3K but not on AKT for
proliferation and survival [34]. The lack of an absolute requirement for
AKT in CRC cells has also been reported. When either PDK1 or AKT1
and AKT2 were knocked out in both HCT116 and DLD-1 cells [35],
the cells were able to survive in standard culture conditions. However,
inhibition of PI3K signaling by pharmacological intervention or
expression of a dominant negative PI3K subunit in the same cell lines
([7] and Figure W2) caused a profound proliferation delay. Overall,
there are clearly cell line–dependent differences in signaling down-
stream of PI3K, and this emphasizes the need to broaden our under-
standing of this important signaling pathway beyond AKT and its
known downstream targets.
The TEC family of kinases is the second largest family of non-
receptor protein tyrosine kinases, comprising five members, namely,
TEC, BTK, ITK, TXK, and BMX (also known as ETK). Whereas
TEC kinases are primarily expressed in hematopoietic cells, BMX
and TEC have a broader expression profile. Specifically, BMX is
expressed in endothelial linages as well as epithelial cancers such as
breast and prostate [36]. All TEC kinases except TXK have a PH
domain that interacts with PtdIns(3,4,5)P3 and can be activated
by PI3K signaling [37–39]. Furthermore, BMX has recently been
implicated in mutant PIK3CA transformation [40]. BMX has been
suggested to have an antiapoptotic function in prostate cancer cell
lines [41], where expression of dominant negative BMX enhances
chemotherapy- and radiotherapy-induced apoptosis. The down-
stream targets of BMX are not fully elucidated; although research
has demonstrated that BMX can activate STAT3 [42] and also bind
to and activate PAK1 [43], whether these targets are responsible for
the antiapoptotic effect of BMX is unclear. BMX has been reported
to bind to BCL-XL in bladder cancer cell lines [44], although the
functional consequences of this interaction and how it is regulated
have not been investigated. In the study reported here, we were
unable to detect any change in phosphorylation of STAT proteins
after treatment with PI3K or TEC kinase inhibitors (data not
shown), and further investigation is now required to understand
the antiapoptotic role of BMX in CRC better.
In addition to BMX, the RNAi library screen identified three
other potential sensitizers to ABT-737, namely, SOS1, SGK1, and
PLEKHB2. Further study with deconvolved SMARTpool siRNA
oligos (Figures 4C and W5) suggested that the efficacy of SOS1
and SGK1 RNAi was probably due to off-target effects of some of
the oligos, rather than knockdown of the intended target. PLEKHB2
was not investigated further as PLEKHB2’s PH domain has recently
been suggested to bind preferentially to phosphatidylserine rather
than PtdIns(3,4,5)P3 [45], and therefore, it is unlikely that PLEKHB2
is a downstream target of PI3K signaling. It is also interesting to note
that knockdown of two PI3K subunits, PIK3CB and PIK3R1, was
implicated in causing resistance to ABT-737 (Figure 4A). One possi-
bility is that down-regulation of specific PI3K subunits (e.g., PIK3CB)
leads to a compensatory up-regulation of other subunits (e.g., PIK3-
CA), and it is the upregulated subunit that drives ABT-737 resistance,
a hypothesis that will be tested in future studies.
From a clinical perspective, the data presented here suggest that
combining navitoclax with PI3K inhibitors or TEC kinase inhibitors
may prove beneficial to patients with metastatic CRC, a population
of patients with a 6% chance of 5-year survival (Colorectal Cancer
Survival by Stage—NCIN Data Briefing 2009, http://tinyurl.com/
pf5hl45), exemplifying the clinical need for improved therapy.
Table 2. Effect of PI3K Pathway Inhibitors on ABT-737 GI50.
Cell Line Treatment ABT-737 GI50 (μM ± 95% CI) Significance*
HCT116 DMSO 4.95 (4.15-5.90)
2 μM PI-103 3.33 (2.88-3.84) 0.0268
2 μM GDC0941 2.73 (2.54-2.93) 0.0036
1 μM AKTi1/2 4.32 (4.17-4.46) 0.2092
1 μM MK2206 4.06 (3.72-4.43) 0.1189
10 nM rapamycin 6.19 (5.77-6.64) 0.0821
2 μM KU0063794 6.57 (6.10-7.07) 0.0441
SW620 DMSO 16.9 (15.4-18.5)
2 μM PI-103 3.15 (2.45-4.05) 0.0002
2 μM GDC0941 6.09 (3.10-11.9) 0.0424
1 μM AKTi1/2 14.5 (11.4-18.5) 0.3140
1 μM MK2206 20.0 (10.6-37.6) 0.6317
10 nM rapamycin 15.3 (12.8-18.4) 0.4049
2 μM KU0063794 16.4 (12.9-20.8) 0.8369
*Two-tailed unpaired t test versus DMSO-treated GI50 for same cell line.
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Figure 4. BMX knockdown and inhibition sensitized to ABT-737. (A) SW620 cells were transfected with an siRNA SMARTpool targeting
1 of 65 mRNA that encode proteins potentially involved in PI3K signaling or a nontargeting control. Forty-eight hours later, cells were
treated with 4 μM ABT-737 or DMSO equivalent for 72 hours, and cellular biomass was determined by SRB staining. Robust z score of
ABT-737–treated cells compared to DMSO control cells was calculated, and the P value for each SMARTpool compared to nontargeting
control was determined by two-tailed unpaired t test. Values for SMARTpool that induce ABT-737 resistance (▲.) and sensitivity (▾) are
shown in right-hand table. (B and C) SW620 cells were transfected with nontargeting siRNA (•), SMARTpool siRNA, or individual oligos
targeting BMX, SOS1, or SGK1 (□), and an ABT-737 concentration response was carried out, or the appropriate mRNA level was deter-
mined by qPCR. B shows the concentration response curve for the most effective siRNA oligo, and C shows the correlation between
knockdown efficiency and ABT-737 efficacy. (D) HCT116 cells were transfected with nontargeting siRNA, BMX siRNA, or MCL-1 siRNA
and the indicated concentration of ABT-737 for 3 days and processed as in Figure 1A. (E) SW620 cells were treated with 4 μM PCI-32765
or DMSO equivalent and the indicated concentration of ABT-737 for 3 days and processed as in Figure 1A. (F) SW620 cells were
transfected with nontargeting siRNA or BMX oligo 1, treated with 2 μM PI-103 or DMSO equivalent and the indicated concentration
of ABT-737 for 3 days, and processed as in Figure 1A. All graphs represent the means of three independent experiments carried out
in triplicate ± SEM.
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However, more research is needed to identify phenotypic and/or geno-
typic traits that predict for combinatorial efficacy. The data presented
here demonstrate that PI3K inhibition increased apoptosis induced by
ABT-737 more in SW620 cells (PIK3CA wild type) than in DLD-1 or
HCT116 cells (PIK3CA mutant). However, we lack sufficient statisti-
cal power to conclude that these differences are due to PIK3CA status
due to the plethora of other genetic differences between the cell lines.
Therefore, to develop predictive biomarkers for this drug combination
expansion to a larger panel of CRC cell lines with known genetic aber-
rations is required.
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Supplemental Materials and Methods
Robust Z Score Calculation
Sensitivity to ABT-737 for each siRNA SMARTPool was assessed
calculating the surviving fraction following treatment with 4 μM ABT-
737 for 72 hours for each siRNA target. Surviving fraction = replicate
well with ABT-737/(average of three replicate wells with DMSO).
The robust z score was used to analyze siRNA screen data. Robust
z score is the number of median absolute deviations (MADs); a value
is from the median value of the data set. The robust z score is used be-
cause it reduces the effect of outliers on the results and prevents missing
potential significant changes in sensitivity to ABT-737. First, the new
surviving fractions are calculated. New surviving fraction = median sur-
viving fraction for all 65 siRNAs − individual surviving fraction.Negative
new surviving fractions are converted to positive values, and the MAD is
then calculated. MAD = SD (new surviving fractions) × 1.4826. The
robust z score for each replicate can be calculated. Robust z score =
[(surviving fraction − median surviving fraction)/MAD] × 1.4826.
Figure W1. Structures of inhibitors used in study. (A) ABT-737, (B) PI-103, (C) GDC-0941, (D) rapamycin, (E) KU-0063794, (F) AKTi1/2,
(G) MK-2206, and (H) PCI-32765.
Figure W2. PI-103 inhibited cell proliferation and PI3K and mTOR signaling. (A) Cells were exposed to the indicated concentration of
PI-103 for 3 days. Cells were fixed and stained with SRB, and the absorbance relative to untreated (UnT) cells was determined. Data
represent the means of three independent experiments carried out in triplicate ± SEM. (B) Cells were exposed to the indicated
concentration of PI-103 for 4 hours, and the effect on level of pS473 PKB, total PKB, pT246 PRAS40, total PRAS40, pS240/244 S6,
and total S6 was determined by Western blot analysis. Results are representative of three independent experiments.
Table W1. Effect of MCL-1 RNAi on ABT-737 GI50.
Cell Line Treatment* ABT-737 GI50
(μM ± 95% CI)
Significance†
vs NT DMSO vs MCL-1 DMSO
HCT116 NT DMSO 5.83 (5.39-6.31)
NT PI-103 3.64 (3.20-4.15) 0.0037
MCL-1 DMSO 3.07 (2.59-3.65) 0.0027
MCL-1 PI-103 1.90 (1.75-2.06) <0.0001 0.0079
SW620 NT DMSO 18.0 (17.1-19.0)
NT PI-103 3.54 (2.75-4.55) 0.0002
MCL-1 DMSO 2.09 (1.76-2.48) <0.0001
MCL-1 PI-103 0.71 (0.56-0.92) <0.0001 0.0022
The table relates to Figures 4B, C , and W6.
*Cells were transfected with either nontargeting siRNA (NT) or MCL-1 targeting siRNA (MCL-1).
Cells were also treated with 2 μM PI-103 or a DMSO equivalent.
†Two-tailed unpaired t test versus indicated treatment for the same cell line.
Figure W3. MCL-1−/− MEFs were sensitized to ABT-737–induced
apoptosis by PI-103. (A) The level ofMCL-1 in parental andMCL-1−/−
MEFs was determined by Western blot analysis. *, nonspecific
background band that acts as a loading control. (B) Parental and
MCL-1−/− MEFs seeded at a low density were exposed to 2 μM
PI-103 and/or 10 μM ABT-737 (parental) or 0.15 μM ABT-737
(MCL-1−/−) for 3 days. Drugs were removed, and cells were
left for 1 week for colonies to form. The number of colonies were
counted and expressed as a surviving fraction relative to DMSO
control. (C) Parental and MCL-1−/− MEFs were exposed to the
same concentrations of PI-103 and ABT-737 as in B for 24 hours
and stained with APC-conjugated annexin V. All graphs repre-
sent the means of three independent experiments carried out in
duplicate ± SEM.
Table W2. Effect of PI3K Activity on ABT-737 GI50.
Cell Line PIK3CA Status ABT-737 GI50 (μM ± 95% CI) Significance*
HCT116 Parental 4.89 (4.55-5.24)
Mutant 8.16 (7.18-9.26) 0.0023
Wild-type 3.40 (3.13-3.71) 0.0031
DLD-1 Parental 7.92 (7.29-8.61)
Mutant 6.97 (5.37-9.04) 0.4085
Wild-type 3.76 (2.96-4.76) 0.0043
The table relates to Figure 3B.
*Two-tailed unpaired t test versus GI50 of parental cells for same cell line.
Figure W5. Neither AKTi1/2 nor rapamycin further sensitized MCL-1 knockdown SW620 cells to ABT-737. SW620 cells were transfected
with NT RNAi or MCL-1 RNAi and plated for experiments 24 hours later. Cells were treated with 1 μM AKTi1/2 (A), 10 nM rapamycin
(Rapa; B), or DMSO equivalent and the indicated concentration of ABT-737 for 3 days and processed as in Figure 1A. All graphs rep-
resent the means of three independent experiments carried out in triplicate ± SEM.
Table W3. Effect of MCL-1 RNAi on ABT-737 GI50.
Cell Line Treatment* ABT-737 GI50
(μM ± 95% CI)
Significance†
vs NT DMSO vs MCL-1 DMSO
SW620 NT DMSO 17.7 (17.3-18.2)
NT AKTi1/2 15.1 (13.0-17.7) 0.12
NT rapamycin 16.2 (14.5-18.1) 0.20
MCL-1 DMSO 2.1 (1.8-2.5) <0.0001
MCL-1 AKTi1/2 1.6 (1.3-2.0) <0.0001 0.11
MCL-1 rapamycin 1.6 (1.3-2.1) <0.0001 0.17
The table relates to Figure W5.
*Cells were transfected with either nontargeting siRNA (NT) or MCL-1 targeting siRNA (MCL-1).
Cells were also treated with 1 μM AKTi1/2 or 10 nM rapamycin or a DMSO equivalent.
†Two-tailed unpaired t test versus indicated treatment for the same cell line.
Figure W4. AKT and mTORC1 inhibition did not effect MCL-1
expression. HCT116 cells were treated with DMSO equivalent, 2 μM
PI-103, 1 μM AKTi1/2, or 10 nM rapamycin for 24 hours, and the
level of MCL-1 and Bad was determined by Western blot analysis.
Table W4. Results of siRNA Screen.
siRNA SMARTpool Robust Z Score P Value
MCL1 −4.669 4.66E-15
SOS1 −1.348 .018
PLEKHB2 −1.213 .030
BMX −1.080 .002
SGK1 −0.944 .006
PIK3R2 −0.915 .074
AKT1 −0.746 .114
PHLDB3 −0.718 .013
PLEKHA2 −0.706 .089
SGK3 −0.649 .032
PIK3CD −0.619 .067
AKT2 −0.535 .147
MCF2 −0.488 .261
DAPP1 −0.484 .156
FGD6 −0.456 .067
PREX2 −0.444 .054
ARAP3 −0.393 .149
VAV2 −0.382 .127
VAV1 −0.359 .140
ARHGEF4 −0.338 .183
DOCK1 −0.311 .336
GSK3B −0.290 .163
PLEKHA1 −0.250 .216
TIAM1 −0.224 .206
PHLDB1 −0.197 .249
ADAP2 −0.186 .305
MTOR −0.169 .320
GAB3 −0.141 .355
PIK3CA −0.127 .419
ARAP1 −0.119 .434
SH3BP2 −0.079 .651
NT −0.077 .539
SGK2 −0.056 .497
ARHGAP1 −0.055 .541
ADAP1 −0.045 .632
RASA2 −0.043 .552
VAV3 −0.025 .559
GSK3A 0.015 .726
SBF1 0.023 .733
PLCXD2 0.029 .732
CYTH4 0.031 .716
PLEK2 0.032 .758
ITK 0.046 .851
TEC 0.049 .796
PTPN9 0.067 .833
GAB1 0.078 .848
ARHGEF6 0.080 .865
SWAP70 0.083 .924
GAB2 0.084 .879
RASA3 0.131 .995
PREX1 0.167 .890
RICTOR 0.223 .830
PDPK1 0.224 .773
DOCK2 0.230 .712
CYTH2 0.301 .519
AKT3 0.303 .580
CYTH1 0.318 .498
ARAP2 0.345 .482
MYO10 0.482 .426
RASA1 0.572 .133
CYTH3 0.612 .201
BTK 0.751 .104
RPTOR 0.825 .075
AKAP13 0.861 .013
PLCL2 1.015 .008
PIK3R1 1.404 .001
PIK3CB 1.571 .002
Figure W6. Deconvolution of BMX, SOS1, and SGK1 SMARTpool. SW620 cells were transfected with nontargeting siRNA, SMARTpool
siRNA, or individual oligos targeting BMX, SOS1, or SGK1, and an ABT-737 concentration response was carried out, or the appropriate
mRNA level was determined by qPCR. (A and B) A shows the concentration response curves, and B shows the correlation between knock-
down efficiency and ABT-737 efficacy. All graphs represent the means of three independent experiments carried out in triplicate ± SEM.
Table W5. ABT-737 GI50 from Deconvolved siRNA Transfection.
RNAi Target Oligo ABT-737 GI50 (μM ± 95% CI) Significance*
Nontargeting SMARTpool 12.04 (10.07-14.10)
BMX 1 6.92 (5.02-9.52) 0.041
2 9.87 (6.06-16.08) 0.496
3 7.42 (6.13-8.99) 0.022
4 8.80 (4.68-16.56) 0.402
SMARTpool 9.38 (8.95-9.83) 0.057
SOS1 1 9.33 (7.87-11.06) 0.113
2 9.42 (8.16-10.91) 0.107
3 7.70 (4.49-13.20) 0.198
4 11.13 (8.98-13.81) 0.613
SMARTpool 9.64 (5.04-18.44) 0.552
SGK1 1 13.11 (11.26-15.26) 0.516
2 9.10 (6.96-11.89) 0.163
3 11.46 (9.26-14.17) 0.744
4 11.58 (8.69-15.44) 0.832
SMARTpool 12.25 (8.85-16.96) 0.931
The table relates to Figures 4, B and C , and W4.
*Two-tailed unpaired t test versus nontargeting siRNA ABT-737 GI50.
Figure W7. BMX RNAi reduced levels of BMX protein. SW620
cells were transfected with BMX siRNA SMARTpool, individual
BMX siRNA oligos, or nontargeting control siRNA SMARTpool. After
48 hours, cells were harvested, and the level of BMX was assayed
byWesternblot analysis. Tubulinwasusedasa loading control. Blots
are representative of three independent experiments.
Table W6. ABT-737 GI50 from HCT116 BMX RNAi.
RNAi Target ABT-737 GI50 (μM ± 95% CI) Significance*
Nontargeting 5.32 (4.40-6.43)
BMX 2.94 (2.83-3.05) 0.027
MCL-1 1.70 (1.28-2.24) 0.022
The table relates to Figure 4D.
*Two-tailed unpaired t test versus nontargeting siRNA ABT-737 GI50.
Table W7. ABT-737 GI50 from SW620, HCT116 and DLD-1 PCI-32765 Treatment.
Cell Line Treatment ABT-737 GI50 (μM ± 95% CI) Significance*
SW620 DMSO 10.8 (10.3-11.2)
4 μM PCI-32765 6.4 (5.9-6.9) 0.0005
HCT116 DMSO 4.2 (3.8-4.7)
4 μM PCI-32765 2.3 (2.0-2.7) 0.005
DLD-1 DMSO 5.4 (5.1-5.8)
4 μM PCI-32765 1.8 (1.7-1.8) >0.0001
The table relates to Figures 4E and W8.
*Two-tailed unpaired t test versus nontargeting DMSO-treated ABT-737 GI50.
Figure W8. PCI-32765 increased the sensitivity of HCT116 and DLD-1 cells to ABT-737. HCT116 and DLD-1 cells were treated with
4 μM PCI-32765 or DMSO equivalent and the indicated concentration of ABT-737 for 3 days and processed as in Figure 1A. All graphs
represent the means of three independent experiments carried out in triplicate. SEM error bars are not visible due to being smaller than
the symbols.
Figure W9. Neither BMX RNAi nor inhibition affected levels of
MCL-1. SW620 cells were transfected with nontargeting siRNA,
BMX siRNA, or MCL-1 siRNA SMARTpool and harvested 48 hours
later to be treated with 4 μM PCI-32765 or DMSO equivalent and
harvested 24 hours later. The level of BMX and MCL-1 was assayed
by Western blot analysis. Tubulin was used as a loading control.
Blots are representative of three independent experiments.
Table W8. ABT-737 GI50 from SW620 BMX RNAi +/− PI-103.
Treatment* ABT-737 GI50 (μM ± 95% CI) Significance
†
vs NT DMSO vs NT PI-103
NT DMSO 15.4 (14.3-16.6)
NT PI-103 3.79 (3.02-4.76) 0.0003
BMX oligo 1 DMSO 8.0 (7.2-8.87) 0.0006
BMX oligo 1 PI-103 2.93 (2.4-3.57) 0.0001 0.171
The table relates to Figure 4F .
*Cells were transfected with either nontargeting siRNA (NT) or BMX oligo 1. Cells were also
treated with 2 μM PI-103 or a DMSO equivalent.
†Two-tailed unpaired t test versus indicated treatment for the same cell line.
